Buy Lupin, target Rs 2510: UBS

UBS maintains a buy rating on Lupin with a 12-month target price of Rs 2510. The performance of US business is likely to improve on new launches. UBS expects strong returns from ongoing investments.

The global investment bank is of the view that in-licensing deals are likely to drive the Indian business. The stock remains one of the top picks in the Indian pharma space.